{"schema_version":"secwatch.filing_event.v1","accession":"0001439222-25-000034","form_type":"8-K","ticker":"AGIO","cik":"0001439222","company_name":"AGIOS PHARMACEUTICALS, INC.","filed_at":"2025-05-01T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.306328+00:00","generated_at":"2026-05-23T00:11:56.931266+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Agios Q1 PYRUKYND revenue $8.7M; PDUFA Sept 7 for thalassemia; net loss $89.3M","bullets":["PYRUKYND net revenue $8.7M in Q1 2025 vs $8.2M in Q1 2024; 136 patients on therapy.","FDA accepted sNDA for thalassemia with PDUFA goal date September 7, 2025; no advisory committee planned.","Phase 3 RISE UP in sickle cell disease topline results expected late 2025; potential US launch in 2026.","Net loss $89.3M in Q1 2025 vs $81.5M in Q1 2024; cash and securities $1.4B as of March 31, 2025.","Krishnan Viswanadhan appointed Chief Corporate Development and Strategy Officer."],"urls":{"canonical":"https://secwatch.observer/filing/0001439222-25-000034","json":"https://secwatch.observer/filing/0001439222-25-000034.json","markdown":"https://secwatch.observer/filing/0001439222-25-000034.md","text":"https://secwatch.observer/filing/0001439222-25-000034.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1439222/000143922225000034/0001439222-25-000034-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1439222/000143922225000034/agio-20250501.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T00:11:56.931266+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}